Diana Ernst, RPh

Most Recent Articles by Diana Ernst, RPh

Supply Updates Announced for Recombivax HBV Vaccines

Supply Updates Announced for Recombivax HBV Vaccines

By

The information, posted to the Food and Drug Administration (FDA) website, states that both the Recombivax HB adult (10mcg/mL) and dialysis (40mcg/mL) formulations are not expected to be available in 2019.

SGLT2 Inhibitors and Urinary Tract Infections: What's the Link?

SGLT2 Inhibitors and Urinary Tract Infections: What's the Link?

By

For this study, the authors identified randomized controlled trials that compared SGLT2 inhibitors with placebo, no treatment, or another antidiabetic agent and reported on UTI outcome.

FDA Approves New Treatment for Travelers' Diarrhea

FDA Approves New Treatment for Travelers' Diarrhea

By

Aemcolo is a broad spectrum, semi-synthetic, orally-administered, minimally-absorbed antibiotic designed to allow for delayed release to the colon.

Afluria, Afluria Quadrivalent Approved for Use in Patients 6 Months and Older

Afluria, Afluria Quadrivalent Approved for Use in Patients 6 Months and Older

By

The vaccines are indicated for active immunization against influenza disease caused by virus subtypes A and type B present in the vaccine.

First-in-Class Antiviral Approved for the Treatment of Influenza

First-in-Class Antiviral Approved for the Treatment of Influenza

By

"This is the first new antiviral flu treatment with a novel mechanism of action approved by the FDA in nearly 20 years," said FDA Commissioner Scott Gottlieb, MD.

More Articles by Diana Ernst, RPh

Sign Up for Free e-newsletters